The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate ...

The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

The Health Resources and Services Administration has issued a warning to Sanofi over its plan to implement a new credit model for sales of certain covered outpatient drugs, threatening to remove the ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest ...

The French drugmaker said that the investment of about 1 billion euros will enhance the production and manufacturing of ...

WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) welcomes the U.S. Health Resources and Services Administration move against Sanofi’s attack on the 340B Drug Pricing Program. In a letter ...

Sanofi SA (SNY) stock saw a decline, ending the day at $46.8 which represents a decrease of $-0.19 or -0.40% from the prior close of $46.99. The stock opened at $47.08 and touched a low of $46.38 ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...

Sanofi’s tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis receives US FDA breakthrough therapy designation: Paris Monday, December 16, 2024, 12:00 Hr ...